Dashboard
Manage Tickers

EOLS Evolus, Inc.

Nasdaq evolus.com


$ 6.63 $ 0.29 (4.53 %)    

Monday, 20-Oct-2025 17:33:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 612.11 $ 7.61 (1.26 %)
DIA $ 467.12 $ 5.24 (1.13 %)
SPY $ 671.75 $ 6.91 (1.04 %)
TLT $ 91.68 $ 0.35 (0.38 %)
GLD $ 401.36 $ 14.16 (3.64 %)
$ 6.69
$ 6.48
$ 6.30 x 800
$ 6.72 x 1
$ 6.45 - $ 6.71
$ 5.71 - $ 17.44
809,436
na
432.75M
$ 1.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-04-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-04-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 02-25-2020 12-31-2019 10-K
24 11-04-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-01-2019 03-31-2019 10-Q
27 03-20-2019 12-31-2018 10-K
28 11-05-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

btig-reiterates-buy-on-evolus-maintains-18-price-target
BTIG Reiterates Buy on Evolus, Maintains $...
09/08/2025 15:49:01

BTIG analyst Sam Eiber reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $18 price target.

evolus-appoints-tatjana-mitchell-as-cfo-effective-september-8-2025
Evolus Appoints Tatjana Mitchell As CFO, E...
09/08/2025 12:32:50

evolus-announces-us-study-of-evolysse-sculpt-met-primary-endpoint-of-non-inferiority-and-showed-statistical-superiority-to-restylane-lyft
Evolus Announces US Study Of Evolysse Scul...
08/25/2025 12:08:41

evolus-submits-final-fda-pma-module-for-evolysse-sculpt-injectable-ha-gel
Evolus Submits Final FDA PMA Module For Ev...
08/20/2025 12:04:13

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, to...

btig-maintains-buy-on-evolus-lowers-price-target-to-18
BTIG Maintains Buy on Evolus, Lowers Price...
08/06/2025 18:02:10

BTIG analyst Sam Eiber maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $21 to $18.

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 17:06:59

needham-downgrades-evolus-to-hold-maintains-price-target-to-22
Needham Downgrades Evolus to Hold, Maintai...
08/06/2025 12:34:49

Needham analyst Serge Belanger downgrades Evolus (NASDAQ:EOLS) from Buy to Hold and maintains the price target from $22 to $22.

super-micro-computer-posts-downbeat-q4-results-joins-personalis-snap-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Super Micro Computer Posts Downbeat Q4 Res...
08/06/2025 12:11:55

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/06/2025 12:08:40

hc-wainwright--co-maintains-buy-on-evolus-lowers-price-target-to-20
HC Wainwright & Co. Maintains Buy on Evolu...
08/06/2025 11:19:24

HC Wainwright & Co. analyst Douglas Tsao maintains Evolus (NASDAQ:EOLS) with a Buy and lowers the price target from $27 ...

why-astera-labs-shares-are-trading-higher-by-over-17-here-are-20-stocks-moving-premarket
Why Astera Labs Shares Are Trading Higher ...
08/06/2025 09:35:31

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/05/2025 21:07:20

evolus-lowers-fy2025-sales-guidance-from-345000m-355000m-to-295000m-305000m-vs-348308m-est
Evolus Lowers FY2025 Sales Guidance from $...
08/05/2025 20:19:00

Evolus (NASDAQ:EOLS) lowers FY2025 sales outlook from $345.000 million-$355.000 million to $295.000 million-$305.000 million vs...

evolus-q2-adj-eps-023-misses-010-estimate-sales-69387m-miss-82182m-estimate
Evolus Q2 Adj. EPS $(0.23) Misses $(0.10) ...
08/05/2025 20:11:26

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.10) by 1...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

a-look-ahead-evoluss-earnings-forecast
A Look Ahead: Evolus's Earnings Forecast
08/04/2025 19:04:07

evolus-announces-study-in-jama-dermatology-finds-jeuveau-outperforms-botox-dysport-and-xeomin-in-onset-peak-effect-and-duration
Evolus Announces Study In "JAMA Dermatolog...
07/31/2025 12:10:18

First head-to-head study of four United States (U.S.) Food & Drug Administration (FDA) approved neurotoxins: Jeuveau®, Boto...

evolus-partners-with-symatese-to-commence-distribution-of-nuceiva-in-france
Evolus Partners With Symatese To Commence ...
07/09/2025 12:04:08

Launching into this key growth market as part of the company's geographic expansion strategyEvolus to provide Nuceiva® to F...

evolus-cfo-sandra-beaver-resigned-company-initiated-service-to-identify-successor
Evolus CFO Sandra Beaver Resigned; Company...
05/27/2025 20:18:05

evolus-publishes-us-pivotal-study-results-for-evolysse-form-and-evolysse-smooth-in-aesthetic-surgery-journal
Evolus Publishes US Pivotal Study Results ...
05/22/2025 12:09:53

Data showed that both Evolysse™ Form and Evolysse™ Smooth met the primary endpoint of non-inferiority1 and demonstrated statist...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION